Q4 2024 Earnings Call Transcript March 20, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.05, ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

By incorporating healthspan science into clinical practice, some doctors are navigating a gray area between mainstream ...

Medical technology company Sibel Health has secured $30m in an equity financing round to expedite the commercial deployment ...

Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...

Minnesota Head & Neck Pain Clinic orofacial pain specialists explain how to overcome challenges in distinguishing between ...

Sibel Health's journey from Northwestern spinout to FDA-cleared medtech innovator showcases Chicago's rising potential in ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Kiffik Biomedical, a leader in interstitial fluid (ISF)-based diagnostics, has announced a strategic partnership with Rubix LS, a pioneer in aptamer-based precision medicine, to develop a first-of-its ...

Becker’s asked C-suite executives from hospitals and health systems across the U.S. to share their biggest lesson from the ...